Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Objective To compare the rate of local eontrol, survival and safety in patients receiving radiotherapy alone (RT) and radiotherapy plus concomitant and adjuvant temozolomide (RT-TMZ) in postoperative patients with glioblastoma. Method 60 postoperative patients with glioblastoma were randomly divided into two groups: RT Group and RT-TMZ Group, each group have 30 patients. The primary end point was overall survial. Results The overall response rate in RT-TMZ Group and RT Group were 53.3% and 26. 6% respeetively. The one-year cumulative local failure rate was 63.3% and 90. 0% respeetively. The one-year free from local failure survival rate was 36.7% and 10. 0% respectively, The one-year survival rate was 56.7% and 16.7% respectively ( P < 0. 05 ). The main side-effect including nausea, vomiting, leueopema, and thrombocytopenia were not serious (grade Ⅰ～Ⅱ ). Conclusions The RT-TMZ Group was well in local control rate, delaying relapse and increasing relapse free survival rate compared with RT Group. The side-effect were little in both groups. Key words: Dmg therapy;  ,Glioblastoma;  Radiotherapy;  Temozolomide